Clinical Trial Update: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial evaluating Emavusertib (CA-4948) in relapsed or refractory primary central nervous system lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Emavusertib (emavusertib)

Snippet

Sponsor: Curis, Inc. | Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1, Phase 2 | Status: RECRUITING